Skip to main content
SpringerLink
Log in

Drug Metabolism

  • Chapter
  • First Online:
The Very Old Critically Ill Patients

Part of the book series: Lessons from the ICU ((LEICU))

  • 756 Accesses

Abstract

With advancing age, various anatomical and physiological changes in several organ systems take place, which may influence drug pharmacokinetics and pharmacodynamics. Elderly patients might have alterations in various pharmacokinetic processes in such a way that drugs need to be dosed differently. Understanding the physiological changes of organ systems that occur with ageing, and consequently the changes in pharmacokinetics and pharmacodynamics, will improve drug therapy in the elderly. Prescribing medication for older people is challenging, as the elderly are more prone to develop adverse drug reactions (ADRs). Important causes of ADRs in elderly patients are multimorbidity and polypharmacy resulting in increased risk for drug-drug interactions. In this chapter we will discuss the alterations in pharmacokinetic processes in elderly patients and the increased potential for ADRs in this population.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. United Nations, Department of economic and social affairs, population Division (2019). World population prospects 2019: highlights (ST/ESA/SER.A/423); 2019.

    Google Scholar 

  2. Waring RH, Harris RM, Mitchell SC. Drug metabolism in the elderly: a multifactorial problem? Maturitas. 2017;100:27–32.

    Article  CAS  PubMed  Google Scholar 

  3. Davies EA, O'Mahony MS. Adverse drug reactions in special populations - the elderly. Br J Clin Pharmacol. 2015;80(4):796–807.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Marengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10(4):430–9.

    Article  PubMed  Google Scholar 

  5. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37–43.

    Article  PubMed  Google Scholar 

  6. McLean G, Gunn J, Wyke S, Guthrie B, Watt GC, Blane DN, et al. The influence of socioeconomic deprivation on multimorbidity at different ages: a cross-sectional study. Br J Gen Pract. 2014;64(624):e440–7.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14(5):447–50.

    Article  CAS  PubMed  Google Scholar 

  8. Cahir C, Bennett K, Teljeur C, Fahey T. Potentially inappropriate prescribing and adverse health outcomes in community dwelling older patients. Br J Clin Pharmacol. 2014;77(1):201–10.

    Article  PubMed  Google Scholar 

  9. Oscanoa TJ, Lizaraso F, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. Eur J Clin Pharmacol. 2017;73(6):759–70.

    Article  CAS  PubMed  Google Scholar 

  10. Wester K, Jonsson A, Spigset O, Hagg S. Spontaneously reported fatal suspected adverse drug reactions: a 10-year survey from Sweden. Pharmacoepidemiol Drug Saf. 2007;16(2):173–80.

    Article  PubMed  Google Scholar 

  11. Wu C, Bell CM, Wodchis WP. Incidence and economic burden of adverse drug reactions among elderly patients in Ontario emergency departments: a retrospective study. Drug Saf. 2012;35(9):769–81.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Collard RM, Boter H, Schoevers RA, Oude Voshaar RC. Prevalence of frailty in community-dwelling older persons: a systematic review. J Am Geriatr Soc. 2012;60(8):1487–92.

    Article  PubMed  Google Scholar 

  13. Flaatten H, de Lange DW, Morandi A, Andersen FH, Artigas A, Bertolini G, et al. The impact of frailty on ICU and 30-day mortality and the level of care in very elderly patients (≥ 80 years). Intensive Care Med. 2017;43(12):1820–8.

    Article  PubMed  Google Scholar 

  14. Herr M, Robine JM, Pinot J, Arvieu JJ, Ankri J. Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people. Pharmacoepidemiol Drug Saf. 2015;24(6):637–46.

    Article  PubMed  Google Scholar 

  15. Saum KU, Schottker B, Meid AD, Holleczek B, Haefeli WE, Hauer K, et al. Is polypharmacy associated with frailty in older people? Results from the ESTHER cohort study. J Am Geriatr Soc. 2017;65(2):e27–32.

    Article  PubMed  Google Scholar 

  16. Hilmer SN. ADME-tox issues for the elderly. Expert Opin Drug Metab Toxicol. 2008;4(10):1321–31.

    Article  CAS  PubMed  Google Scholar 

  17. Buch A, Carmeli E, Boker LK, Marcus Y, Shefer G, Kis O, et al. Muscle function and fat content in relation to sarcopenia, obesity and frailty of old age--An overview. Exp Gerontol. 2016;76:25–32.

    Article  PubMed  Google Scholar 

  18. Marzetti E, Calvani R, Tosato M, Cesari M, Di Bari M, Cherubini A, et al. Sarcopenia: an overview. Aging Clin Exp Res. 2017;29(1):11–7.

    Article  PubMed  Google Scholar 

  19. Cesari M, Leeuwenburgh C, Lauretani F, Onder G, Bandinelli S, Maraldi C, et al. Frailty syndrome and skeletal muscle: results from the Invecchiare in chianti study. Am J Clin Nutr. 2006;83(5):1142–8.

    Article  CAS  PubMed  Google Scholar 

  20. Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Johnston C, Kirkpatrick CM, McLachlan AJ, Hilmer SN. Physiologically based pharmacokinetic modeling at the extremes of age. Clin Pharmacol Ther. 2013;93(2):148.

    Article  CAS  PubMed  Google Scholar 

  22. Hurwitz A, Brady DA, Schaal SE, Samloff IM, Dedon J, Ruhl CE. Gastric acidity in older adults. JAMA. 1997;278(8):659–62.

    Article  CAS  PubMed  Google Scholar 

  23. Nakamura K, Ogoshi K, Makuuchi H. Influence of aging, gastric mucosal atrophy and dietary habits on gastric secretion. Hepato-Gastroenterology. 2006;53(70):624–8.

    PubMed  Google Scholar 

  24. Hurwitz A, Ruhl CE, Kimler BF, Topp EM, Mayo MS. Gastric function in the elderly: effects on absorption of ketoconazole. J Clin Pharmacol. 2003;43(9):996–1002.

    Article  CAS  PubMed  Google Scholar 

  25. Tay HS, Soiza RL. Systematic review and meta-analysis: what is the evidence for oral iron supplementation in treating anaemia in elderly people? Drugs Aging. 2015;32(2):149–58.

    Article  CAS  PubMed  Google Scholar 

  26. Gainsborough N, Maskrey VL, Nelson ML, Keating J, Sherwood RA, Jackson SH, et al. The association of age with gastric emptying. Age Ageing. 1993;22(1):37–40.

    Article  CAS  PubMed  Google Scholar 

  27. Soenen S, Rayner CK, Horowitz M, Jones KL. Gastric emptying in the elderly. Clin Geriatr Med. 2015;31(3):339–53.

    Article  PubMed  Google Scholar 

  28. Husebye E, Engedal K. The patterns of motility are maintained in the human small intestine throughout the process of aging. Scand J Gastroenterol. 1992;27(5):397–404.

    Article  CAS  PubMed  Google Scholar 

  29. O'Mahony D, O'Leary P, Quigley EM. Aging and intestinal motility: a review of factors that affect intestinal motility in the aged. Drugs Aging. 2002;19(7):515–27.

    Article  PubMed  Google Scholar 

  30. Saltzman JR, Kowdley KV, Perrone G, Russell RM. Changes in small-intestine permeability with aging. J Am Geriatr Soc. 1995;43(2):160–4.

    Article  CAS  PubMed  Google Scholar 

  31. Valentini L, Ramminger S, Haas V, Postrach E, Werich M, Fischer A, et al. Small intestinal permeability in older adults. Physiol Rep. 2014;2(4):e00281.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Yuasa H, Soga N, Kimura Y, Watanabe J. Effect of aging on the intestinal transport of hydrophilic drugs in the rat small intestine. Biol Pharm Bull. 1997;20(11):1188–92.

    Article  CAS  PubMed  Google Scholar 

  33. Schmucker DL. Aging and drug disposition: an update. Pharmacol Rev. 1985;37(2):133–48.

    CAS  PubMed  Google Scholar 

  34. Hollander D, Tarnawski H. Aging-associated increase in intestinal absorption of macromolecules. Gerontology. 1985;31(3):133–7.

    Article  CAS  PubMed  Google Scholar 

  35. Armbrecht HJ, Boltz MA, Kumar VB. Intestinal plasma membrane calcium pump protein and its induction by 1,25(OH)(2)D(3) decrease with age. Am J Phys. 1999;277(1):G41–7.

    CAS  Google Scholar 

  36. Toyoshima M, Inada M, Kameyama M. Effects of aging on intracellular transport of vitamin B12 (B12) in rat enterocytes. J Nutr Sci Vitaminol (Tokyo). 1983;29(1):1–10.

    Article  CAS  Google Scholar 

  37. Doherty MM, Charman WN. The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin Pharmacokinet. 2002;41(4):235–53.

    Article  CAS  PubMed  Google Scholar 

  38. Mangoni AA. The impact of advancing age on P-glycoprotein expression and activity: current knowledge and future directions. Expert Opin Drug Metab Toxicol. 2007;3(3):315–20.

    Article  CAS  PubMed  Google Scholar 

  39. Madsen JL. Effects of gender, age, and body mass index on gastrointestinal transit times. Dig Dis Sci. 1992;37(10):1548–53.

    Article  CAS  PubMed  Google Scholar 

  40. Madsen JL, Graff J. Effects of ageing on gastrointestinal motor function. Age Ageing. 2004;33(2):154–9.

    Article  PubMed  Google Scholar 

  41. Konda S, Meier-Davis SR, Cayme B, Shudo J, Maibach HI. Age-related percutaneous penetration part 2: effect of age on dermatopharmacokinetics and overview of transdermal products. Skin Therapy Lett. 2012;17(6):5–7.

    CAS  PubMed  Google Scholar 

  42. Tanner T, Marks R. Delivering drugs by the transdermal route: review and comment. Skin Res Technol. 2008;14(3):249–60.

    Article  CAS  PubMed  Google Scholar 

  43. Kaestli LZ, Wasilewski-Rasca AF, Bonnabry P, Vogt-Ferrier N. Use of transdermal drug formulations in the elderly. Drugs Aging. 2008;25(4):269–80.

    Article  CAS  PubMed  Google Scholar 

  44. Nelson L, Schwaner R. Transdermal fentanyl: pharmacology and toxicology. J Med Toxicol. 2009;5(4):230–41.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Skloot GS. The effects of aging on lung structure and function. Clin Geriatr Med. 2017;33(4):447–57.

    Article  PubMed  Google Scholar 

  46. Allen S. Are inhaled systemic therapies a viable option for the treatment of the elderly patient? Drugs Aging. 2008;25(2):89–94.

    Article  PubMed  Google Scholar 

  47. Wilkinson GR. The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans. Adv Drug Deliv Rev. 1997;27:129–59.

    Article  CAS  PubMed  Google Scholar 

  48. Prommer E. Role of codeine in palliative care. J Opioid Manag. 2011;7(5):401–6.

    Article  PubMed  Google Scholar 

  49. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2004;19(1):117–25.

    Article  CAS  Google Scholar 

  50. Davies RO, Gomez HJ, Irvin JD, Walker JF. An overview of the clinical pharmacology of enalapril. Br J Clin Pharmacol. 1984;18(Suppl 2):215S–29S.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Todd PA, Perindopril FA. A review of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs. 1991;42(1):90–114.

    Article  CAS  PubMed  Google Scholar 

  52. Fulop T Jr, Worum I, Csongor J, Foris G, Leovey A. Body composition in elderly people. I. Determination of body composition by multiisotope method and the elimination kinetics of these isotopes in healthy elderly subjects. Gerontology. 1985;31(1):6–14.

    PubMed  Google Scholar 

  53. Reeve E, Wiese MD, Mangoni AA. Alterations in drug disposition in older adults. Expert Opin Drug Metab Toxicol. 2015;11(4):491–508.

    Article  PubMed  Google Scholar 

  54. Cusack B, Kelly J, O'Malley K, Noel J, Lavan J, Horgan J. Digoxin in the elderly: pharmacokinetic consequences of old age. Clin Pharmacol Ther. 1979;25(6):772–6.

    Article  CAS  PubMed  Google Scholar 

  55. Drenth-van Maanen AC, Wilting I, Jansen PAF. Prescribing medicines to older people-how to consider the impact of ageing on human organ and body functions. Br J Clin Pharmacol. 2020;86(10):1921–30.

    Article  PubMed  Google Scholar 

  56. Jansen PA, Brouwers JR. Clinical pharmacology in old persons. Scientifica (Cairo). 2012;2012:723678.

    Google Scholar 

  57. Redolfi A, Borgogelli E, Lodola E. Blood level of cimetidine in relation to age. Eur J Clin Pharmacol. 1979;15(4):257–61.

    Article  CAS  PubMed  Google Scholar 

  58. Vestal RE, McGuire EA, Tobin JD, Andres R, Norris AH, Mezey E. Aging and ethanol metabolism. Clin Pharmacol Ther. 1977;21(3):343–54.

    Article  CAS  PubMed  Google Scholar 

  59. Herman RJ, Wilkinson GR. Disposition of diazepam in young and elderly subjects after acute and chronic dosing. Br J Clin Pharmacol. 1996;42(2):147–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Toornvliet R, van Berckel BN, Luurtsema G, Lubberink M, Geldof AA, Bosch TM, et al. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther. 2006;79(6):540–8.

    Article  CAS  PubMed  Google Scholar 

  61. Schinkel AH. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev. 1999;36(2–3):179–94.

    Article  CAS  PubMed  Google Scholar 

  62. Butler JM, Begg EJ. Free drug metabolic clearance in elderly people. Clin Pharmacokinet. 2008;47(5):297–321.

    Article  CAS  PubMed  Google Scholar 

  63. Greenblatt DJ. Reduced serum albumin concentration in the elderly: a report from the Boston collaborative drug surveillance program. J Am Geriatr Soc. 1979;27(1):20–2.

    Article  CAS  PubMed  Google Scholar 

  64. Weaving G, Batstone GF, Jones RG. Age and sex variation in serum albumin concentration: an observational study. Ann Clin Biochem. 2016;53(1):106–11.

    Article  CAS  PubMed  Google Scholar 

  65. Smith SA, Waters NJ. Pharmacokinetic and Pharmacodynamic considerations for drugs binding to Alpha-1-acid glycoprotein. Pharm Res. 2019;36(2):30.

    Article  CAS  Google Scholar 

  66. Tenero DM, Bottorff MB, Burlew BS, Williams JB, Lalonde RL. Altered beta-adrenergic sensitivity and protein binding to 1-propranolol in the elderly. J Cardiovasc Pharmacol. 1990;16(5):702–7.

    Article  CAS  PubMed  Google Scholar 

  67. Woo J, Chan HS, Or KH, Arumanayagam M. Effect of age and disease on two drug binding proteins: albumin and alpha-1- acid glycoprotein. Clin Biochem. 1994;27(4):289–92.

    Article  CAS  PubMed  Google Scholar 

  68. Le Couteur DG, McLean AJ. The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet. 1998;34(5):359–73.

    PubMed  Google Scholar 

  69. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev. 2004;56(2):163–84.

    Article  CAS  PubMed  Google Scholar 

  70. Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol. 2001;15(6):897–918.

    Article  CAS  PubMed  Google Scholar 

  71. Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab. 2011;12(7):601–10.

    Article  CAS  PubMed  Google Scholar 

  72. Schmucker DL. Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging. 2001;18(11):837–51.

    Article  CAS  PubMed  Google Scholar 

  73. George J, Byth K, Farrell GC. Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochem Pharmacol. 1995;50(5):727–30.

    Article  CAS  PubMed  Google Scholar 

  74. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther. 1997;61(3):331–9.

    Article  CAS  PubMed  Google Scholar 

  75. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol. 1992;44(2):275–83.

    Article  CAS  PubMed  Google Scholar 

  76. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67–76.

    Article  CAS  PubMed  Google Scholar 

  77. Schmucker DL, Woodhouse KW, Wang RK, Wynne H, James OF, McManus M, et al. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther. 1990;48(4):365–74.

    Article  CAS  PubMed  Google Scholar 

  78. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270(1):414–23.

    CAS  PubMed  Google Scholar 

  79. Hilmer SN, Wu H, Zhang M. Biology of frailty: implications for clinical pharmacology and drug therapy in frail older people. Mech Ageing Dev. 2019;181:22–8.

    Article  CAS  PubMed  Google Scholar 

  80. Hubbard RE, O'Mahony MS, Calver BL, Woodhouse KW. Plasma esterases and inflammation in ageing and frailty. Eur J Clin Pharmacol. 2008;64(9):895–900.

    Article  CAS  PubMed  Google Scholar 

  81. Schwartz JB. Erythromycin breath test results in elderly, very elderly, and frail elderly persons. Clin Pharmacol Ther. 2006;79(5):440–8.

    Article  CAS  PubMed  Google Scholar 

  82. Renton KW. Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol. 2005;1(4):629–40.

    Article  CAS  PubMed  Google Scholar 

  83. Herd B, Wynne H, Wright P, James O, Woodhouse K. The effect of age on glucuronidation and sulphation of paracetamol by human liver fractions. Br J Clin Pharmacol. 1991;32(6):768–70.

    CAS  PubMed  PubMed Central  Google Scholar 

  84. Divoll M, Greenblatt DJ, Harmatz JS, Shader RI. Effect of age and gender on disposition of temazepam. J Pharm Sci. 1981;70(10):1104–7.

    Article  CAS  PubMed  Google Scholar 

  85. Ghabrial H, Desmond PV, Watson KJ, Gijsbers AJ, Harman PJ, Breen KJ, et al. The effects of age and chronic liver disease on the elimination of temazepam. Eur J Clin Pharmacol. 1986;30(1):93–7.

    Article  CAS  PubMed  Google Scholar 

  86. Wynne HA, Yelland C, Cope LH, Boddy A, Woodhouse KW, Bateman DN. The association of age and frailty with the pharmacokinetics and pharmacodynamics of metoclopramide. Age Ageing. 1993;22(5):354–9.

    Article  CAS  PubMed  Google Scholar 

  87. Wynne HA, Cope LH, Herd B, Rawlins MD, James OF, Woodhouse KW. The association of age and frailty with paracetamol conjugation in man. Age Ageing. 1990;19(6):419–24.

    Article  CAS  PubMed  Google Scholar 

  88. Mitchell SJ, Kane AE, Hilmer SN. Age-related changes in the hepatic pharmacology and toxicology of paracetamol. Curr Gerontol Geriatr Res. 2011;2011:624156.

    PubMed  PubMed Central  Google Scholar 

  89. Seripa D, Pilotto A, Panza F, Matera MG, Pilotto A. Pharmacogenetics of cytochrome P450 (CYP) in the elderly. Ageing Res Rev. 2010;9(4):457–74.

    Article  CAS  PubMed  Google Scholar 

  90. Tannenbaum C, Sheehan NL. Understanding and preventing drug-drug and drug-gene interactions. Expert Rev Clin Pharmacol. 2014;7(4):533–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Elliott LS, Henderson JC, Neradilek MB, Moyer NA, Ashcraft KC, Thirumaran RK. Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: a prospective pilot randomized controlled trial. PLoS One. 2017;12(2):e0170905.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  92. Ducker CM, Brockmoller J. Genomic variation and pharmacokinetics in old age: a quantitative review of age- vs. Genotype-related differences. Clin Pharmacol Ther. 2019;105(3):625–40.

    Article  PubMed  Google Scholar 

  93. Empey PE. Genetic predisposition to adverse drug reactions in the intensive care unit. Crit Care Med. 2010;38(6 Suppl):S106–16.

    Article  CAS  PubMed  Google Scholar 

  94. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33(4):278–85.

    Article  CAS  PubMed  Google Scholar 

  95. Muhlberg W, Platt D. Age-dependent changes of the kidneys: pharmacological implications. Gerontology. 1999;45(5):243–53.

    Article  CAS  PubMed  Google Scholar 

  96. Fliser D. Ren sanus in corpore Sano: the myth of the inexorable decline of renal function with senescence. Nephrol Dial Transplant. 2005;20(3):482–5.

    Article  PubMed  Google Scholar 

  97. Sesso R, Prado F, Vicioso B, Ramos LR. Prospective study of progression of kidney dysfunction in community-dwelling older adults. Nephrology (Carlton). 2008;13(2):99–103.

    Article  CAS  Google Scholar 

  98. Englund G, Hallberg P, Artursson P, Michaelsson K, Melhus H. Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring. BMC Med. 2004;2:8.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Bolignano D, Mattace-Raso F, Sijbrands EJ, Zoccali C. The aging kidney revisited: a systematic review. Ageing Res Rev. 2014;14:65–80.

    Article  CAS  PubMed  Google Scholar 

  100. Sproule BA, Hardy BG, Shulman KI. Differential pharmacokinetics of lithium in elderly patients. Drugs Aging. 2000;16(3):165–77.

    Article  CAS  PubMed  Google Scholar 

  101. Currie GM, Wheat JM, Kiat H. Pharmacokinetic considerations for digoxin in older people. Open Cardiovasc Med J. 2011;5:130–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Tueth MJ, Murphy TK, Evans DL. Special considerations: use of lithium in children, adolescents, and elderly populations. J Clin Psychiatry. 1998;59(Suppl 6):66–73.

    CAS  PubMed  Google Scholar 

  103. Triggs E, Charles B. Pharmacokinetics and therapeutic drug monitoring of gentamicin in the elderly. Clin Pharmacokinet. 1999;37(4):331–41.

    Article  CAS  PubMed  Google Scholar 

  104. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med. 2012;366(9):864–6.

    Article  CAS  PubMed  Google Scholar 

  105. Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, et al. Acute skeletal muscle wasting in critical illness. JAMA. 2013;310(15):1591–600.

    Article  CAS  PubMed  Google Scholar 

  106. Fliser D, Bischoff I, Hanses A, Block S, Joest M, Ritz E, et al. Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. Eur J Clin Pharmacol. 1999;55(3):205–11.

    Article  CAS  PubMed  Google Scholar 

  107. Johnston C, Hilmer SN, McLachlan AJ, Matthews ST, Carroll PR, Kirkpatrick CM. The impact of frailty on pharmacokinetics in older people: using gentamicin population pharmacokinetic modeling to investigate changes in renal drug clearance by glomerular filtration. Eur J Clin Pharmacol. 2014;70(5):549–55.

    Article  CAS  PubMed  Google Scholar 

  108. van Marum RJ. Underrepresentation of the elderly in clinical trials, time for action. Br J Clin Pharmacol. 2020;86(10):2014–6.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Medical Center Utrecht, Dutch Poisons Information Center (DPIC), Utrecht, The Netherlands

    Saskia Rietjens

  2. University Medical Center Utrecht, Dutch Poisons Information Center (DPIC), Utrecht, The Netherlands

    Dylan de Lange

Authors
  1. Saskia Rietjens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dylan de Lange
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Saskia Rietjens .

Editor information

Editors and Affiliations

  1. Faculty of Medicine, Department of Clinical Medicine and Department of Anaesthesia and Intensive Care, University of Bergen and Haukeland University Hospital, Bergen, Norway

    Hans Flaatten

  2. Sorbonne Université, INSERM Institut Pierre Louis d’Epidémiologie et de, Santé Publique, AP-HP, Hôpital Saint Antoine, Paris, France

    Bertrand Guidet

  3. Sorbonne Université, Hôpital Saint Antoine Unité de Gériatrie Aiguë, Assistance Publique, Hôpitaux de Paris, Paris, France

    Hélène Vallet

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rietjens, S., de Lange, D. (2022). Drug Metabolism. In: Flaatten, H., Guidet, B., Vallet, H. (eds) The Very Old Critically Ill Patients. Lessons from the ICU. Springer, Cham. https://doi.org/10.1007/978-3-030-94133-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-94133-8_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-94132-1

  • Online ISBN: 978-3-030-94133-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation